Recombinant high-density lipoprotein nanoparticles containing gadolinium-labeled cholesterol for morphologic and functional magnetic resonance imaging of the liver

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3751-3768

  Rui, Mengjie ^a   Guo, Wei ^b   Ding, Qian ^b   Wei, Xiaohui ^b   Xu, Jianrong ^b   Xu, Yuhong ^b  

^a School of Life Science and Biotechnology   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Apolipoprotein; Contrast agent; Gadolinium; High density lipoprotein; Liver; Magnetic resonance imaging

Indexed keywords

CHOLESTEROL; GADOLINIUM; HIGH DENSITY LIPOPROTEIN NANOPARTICLE; HIGH DENSITY LIPOPROTEIN RECEPTOR; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL VIABILITY; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG STRUCTURE; ELECTRON SPIN RESONANCE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; RAT; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; CELL SURVIVAL; CHOLESTEROL; CONTRAST MEDIA; GADOLINIUM DTPA; HEP G2 CELLS; HUMANS; LIPOPROTEINS, HDL; LIVER; MAGNETIC RESONANCE IMAGING; MAGNETICS; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

RATTUS;

EID: 84870359345     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S33139     Document Type: Article

References (55)

1. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99(9):2293-2352.
2. Geraldes CF, Laurent S. Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol Imaging. 2009;4(1):1-23.
3. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics. 2009;29(6):1725-1748.
4. Langereis S, Dirksen A, Hackeng TM, van Genderen MHP, Meijer EW. Dendrimers and magnetic resonance imaging. New J Chem. 2007;31(7): 1152-1160.
5. Luo K, Liu G, He B, etal. Multifunctional gadolinium-based dendritic macromolecules as liver targeting imaging probes. Biomaterials. 2011; 32(10):2575-2585.
6. Rensen PCN, de Vrueh RLA, Kuiper J, Bijsterbosch MK, Biessen EAL, van Berkel TJC. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev. 2001;47(2-3):251-276.
7. Zhou P, Hatziieremia S, Elliott MA, etal. Uptake of synthetic low density lipoprotein by leukemic stem cells-a potential stem cell targeted drug delivery strategy. J Control Release. 2010;148(3):380-387.
8. Maximov VD, Reukov VV, Barry JN, Cochrane C, Vertegel AA. Protein-nanoparticle conjugates as potential therapeutic agents for the treatment of hyperlipidemia. Nanotechnology. 2010;21(26):265103.
9. Crich SG, Lanzardo S, Alberti D, etal. Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles. Neoplasia. 2007;9(12):1046-1056.
10. Zhang X, Chen B. Recombinant high density lipoprotein reconstituted with apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin. Cancer Lett. 2010;298(1):26-33.
11. Feng M, Cai Q, Huang H, Zhou P. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur J Pharm Biopharm. 2008;68(3):688-693.
12. Oda MN, Hargreaves PL, Beckstead JA, Redmond KA, van Antwerpen R, Ryan RO. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J Lipid Res. 2006;47(2):260-267.
13. Firestone RA. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem. 1994;5(2): 105-113.
14. van der Velde AE. Reverse cholesterol transport: from classical view to new insights. World J Gastroenterol. 2010;16(47):5908-5915.
15. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc. 2004;126(50):16316-16317.
16. Cormode DP, Chandrasekar R, Delshad A, etal. Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. Bioconjug Chem. 2009;20(5):937-943.
17. Cormode DP, Skajaa T, van Schooneveld MM, etal. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett. 2008;8(11):3715-3723.
18. Skajaa T, Cormode DP, Jarzyna PA, etal. The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. Biomaterials. 2011;32(1):206-213.
19. Sriram R, Lagerstedt JO, Petrlova J, etal. Imaging apolipoprotein AI in vivo. NMR Biomed. 2011;24(7):916-924.
20. Roma P, Gregg RE, Meng MS, etal. In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-I Milano, associated with familial hypoalphalipoproteinemia. J Clin Invest. 1993;91(4):1445-1452.
21. Malmendier CL, Delcroix C, Ameryckx JP. In vivo metabolism of human apoprotein A-I-phospholipid complexes. Comparison with human high density lipoprotein-apoprotein A-I metabolism. Clin Chim Acta. 1983;131(3):201-210.
22. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20(6):563-576.
23. Ryan RO, Forte TM, Oda MN. Optimized bacterial expression of human apolipoprotein A-I. Protein Expr Purif. 2003;27(1):98-103.
24. Waterhouse JE, Harbottle RP, Keller M, etal. Synthesis and application of integrin targeting lipopeptides in targeted gene delivery. Chembiochem. 2005;6(7):1212-1223.
25. Funk GM, Hunt CE, Epps DE, Brown PK. Use of a rapid and highly sensitive fluorescamine-based procedure for the assay of plasma lipoproteins. J Lipid Res. 1986;27(7):792-795.
26. Nagaraja TN, Croxen RL, Panda S, etal. Application of arsenazo III in the preparation and characterization of an albumin-linked, gadolinium-based macromolecular magnetic resonance contrast agent. J Neurosci Methods. 2006;157(2):238-245.
27. Forte TM, Nordhausen RW. Electron microscopy of negatively stained lipoproteins. Methods Enzymol. 1986;128:442-457.
28. Tamat SR, Moore DE, Allen BJ. Determination of boron in biological tissues by inductively coupled plasma atomic emission spectrometry. Anal Chem. 1987;59(17):2161-2164.
29. Nichols AV, Krauss RM, Musliner TA. Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol. 1986;128:417-431.
30. Maximov VD, Reukov VV, Barry JN, Cochrane C, Vertegel AA. Protein-nanoparticle conjugates as potential therapeutic agents for the treatment of hyperlipidemia. Nanotechnology. 2010;21(26):265103.
31. Forte TM, Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm. 2007;328(1):86-94.
32. Ji B, Peacock G, Lu DR. Synthesis of cholesterol-carborane conjugate for targeted drug delivery. Bioorg Med Chem Lett. 2002;12(17): 2455-2458.
33. Chu ACY, Tsang SY, Lo EHK, Fung KP. Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Life Sci. 2001;70(5):591-601.
34. Callahan DE, Forte TM, Afzal SM, etal. Boronated protoporphyrin (BOPP): localization in lysosomes of the human glioma cell line SF-767 with uptake modulated by lipoprotein levels. Int J Radiat Oncol Biol Phys. 1999;45(3):761-771.
35. Vitols S, Soderberg-Reid K, Masquelier M, Sjostrom B, Peterson C. Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. Br J Cancer. 1990;62(5):724-729.
36. Lee H, Kim SI, Shin D, etal. Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice. Biochem Biophys Res Commun. 2009;378(2):192-196.
37. Feng MQ, Cai QS, Shi XL, Huang H, Zhou P, Guo X. Recombinant high-density lipoprotein complex as a targeting system of nosiheptide to liver cells. J Drug Target. 2008;16(6):502-508.
38. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 1980;209(4455):497-499.
39. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979;282(5739):615-616.
40. Mersch-Sundermann V, Knasmuller S, Wu XJ, Darroudi F, Kassie F. Use of a human-derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agents. Toxicology. 2004;198(1-3): 329-340.
41. Rhainds D, Bourgeois P, Bourret G, Huard K, Falstrault L, Brissette L. Localization and regulation of SR-BI in membrane rafts of HepG2cells. J Cell Sci. 2004;117(Pt 15):3095-3105.
42. Vantourout P, Radojkovic C, Lichtenstein L, Pons V, Champagne E, Martinez LO. Ecto-F-ATPase: a moonlighting protein complex and an unexpected apoA-I receptor. World J Gastroenterol. 2010;16(47): 5925-5935.
43. Connolly DT, Krul ES, Heuvelman D, Glenn KC. Inhibition of cholesteryl ester transfer protein by apolipoproteins, lipopolysaccharides, and cholesteryl sulfate. Biochim Biophys Acta. 1996;1304(2):145-160.
44. Stark DD, Weissleder R, Elizondo G, etal. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology. 1988;168(2):297-301.
45. Cittadino E, Ferraretto M, Torres E, etal. MRI evaluation of the antitumor activity of paramagnetic liposomes loaded with prednisolone phosphate. Eur J Pharm Sci. 2012;45(4):436-441.
46. Luo K, Liu G, She WC, etal. Gadolinium-labeled peptide dendrimers with controlled structures as potential magnetic resonance imaging contrast agents. Biomaterials. 2011;32(31):7951-7960.
47. Kobayashi H, Brechbiel MW. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev. 2005;57(15):2271-2286.
48. Chen ZJ, Yu DX, Liu CX, etal. Gadolinium-conjugated PLA-PEG nanoparticles as liver targeted molecular MRI contrast agent. J Drug Target. 2011;19(8):657-665.
49. Lee NK, Kim S, Lee JW, etal. Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. Radiographics. 2009;29(6):1707-1724.
50. Ryeom HK, Kim SH, Kim JY, etal. Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol. 2004;5(4):231-239.
51. Schuhmann-Giamperi G. Liver contrast media for magnetic resonance imaging: interrelations between pharmacokinetics and imaging. Invest Radiol. 1993;28(8):753-761.
52. Leonhardt M, Keiser M, Oswald S, etal. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos. 2010;38(7):1024-1028.
53. Clement O, Muhler A, Vexler V, Berthezene Y, Brasch RC. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. Invest Radiol. 1992;27(8):612-619.
54. Evenepoel P, Zeegers M, Segaert S, etal. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant. 2004;19(2):469-473.
55. Cowper SE. Nephrogenic systemic fibrosis: an overview. J Am Coll Radiol. 2008;5(1):23-28.